Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (66)
  • Open Access

    ARTICLE

    CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression

    JUNZHE YI1,#, BINBIN LI2,#, XIAOMIN YIN3, LINGRUI LIU1, CAILU SONG1, YING ZHAO4, MANBO CAI3, HAILIN TANG1, DONG CHEN4,*, NING LYU1,*

    Oncology Research, Vol.32, No.6, pp. 1129-1139, 2024, DOI:10.32604/or.2024.047524

    Abstract Circular RNAs (circRNAs) have been recognized as pivotal regulators in tumorigenesis, yet the biological functions as well as molecular mechanisms of the majority of circRNAs in hepatocellular carcinoma (HCC) remain elusive. We sought to unveil the expression profile and biological role of circMYBL2 in HCC. Initial microarray analyses were conducted to probe the expression profile of circMYBL2 in HCC cells, and qRT‒PCR analysis was then performed in HCC cell lines and tissues, revealing significant upregulation of circMYBL2. Subsequent experiments were conducted to evaluate the biological function of circMYBL2 in HCC progression. Furthermore, bioinformatics analysis, qRT‒PCR… More >

  • Open Access

    ARTICLE

    PHLDA2 reshapes the immune microenvironment and induces drug resistance in hepatocellular carcinoma

    KUN FENG1,#, HAO PENG2,#, QINGPENG LV1, YEWEI ZHANG1,*

    Oncology Research, Vol.32, No.6, pp. 1063-1078, 2024, DOI:10.32604/or.2024.047078

    Abstract Hepatocellular carcinoma (HCC) is a malignancy known for its unfavorable prognosis. The dysregulation of the tumor microenvironment (TME) can affect the sensitivity to immunotherapy or chemotherapy, leading to treatment failure. The elucidation of PHLDA2’s involvement in HCC is imperative, and the clinical value of PHLDA2 is also underestimated. Here, bioinformatics analysis was performed in multiple cohorts to explore the phenotype and mechanism through which PHLDA2 may affect the progression of HCC. Then, the expression and function of PHLDA2 were examined via the qRT-PCR, Western Blot, and MTT assays. Our findings indicate a substantial upregulation of… More >

  • Open Access

    ARTICLE

    Identification prognostic features related to sphingolipid metabolism and experimental validation of TRIM47 in hepatocellular carcinoma

    JIAN TANG1, CHENQIANG ZHU1, YUN CHEN1, YUNLONG WU1, MING HE1, YI ZHOU2, MINGHUA XIE2,*

    BIOCELL, Vol.48, No.4, pp. 639-651, 2024, DOI:10.32604/biocell.2024.047562

    Abstract Background: The specific impact of sphingolipid metabolism on developing hepatocellular Carcinoma (HCC) remains unclear. This study aims to explore the relationship between sphingolipid metabolism and HCC prognosis, immune response, and drug sensitivity. Methods: Data were obtained from The Cancer Genome Atlas (TCGA)-Hepatocellular Carcinoma (LIHC) and Gene Expression Omnibus (GEO, GSE14520 datasets). 47 sphingolipid metabolism genes were obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. After classifying HCC samples using the Non-negative Matrix Factorization (NMF) clustering method, differentially expressed genes were screened. Then, 8 risk genes were obtained by univariate analysis, survival random forest… More > Graphic Abstract

    Identification prognostic features related to sphingolipid metabolism and experimental validation of TRIM47 in hepatocellular carcinoma

  • Open Access

    ARTICLE

    Degradation of FAK-targeting by proteolytic targeting chimera technology to inhibit the metastasis of hepatocellular carcinoma

    XINFENG ZHANG1,2,#, SHUANG LI2,#, MEIRU SONG1,2, YUE CHEN3, LIANGZHENG CHANG3, ZHERUI LIU4, HONGYUAN DAI3, YUTAO WANG4, GANGQI YANG3, YUN JIANG5,6,*, YINYING LU1,2,*

    Oncology Research, Vol.32, No.4, pp. 679-690, 2024, DOI:10.32604/or.2024.046231

    Abstract Liver cancer is a prevalent malignant cancer, ranking third in terms of mortality rate. Metastasis and recurrence primarily contribute to the high mortality rate of liver cancer. Hepatocellular carcinoma (HCC) has low expression of focal adhesion kinase (FAK), which increases the risk of metastasis and recurrence. Nevertheless, the efficacy of FAK phosphorylation inhibitors is currently limited. Thus, investigating the mechanisms by which FAK affects HCC metastasis to develop targeted therapies for FAK may present a novel strategy to inhibit HCC metastasis. This study examined the correlation between FAK expression and the prognosis of HCC. Additionally,… More >

  • Open Access

    ARTICLE

    Investigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma

    JUN LIU1,2,3,#, WENLI LI3, RUYUE LU1,2, JIAQING XU1,2, CHUNHUI JIANG4, JUNLIN DUAN3, LINGZHI ZHANG1,#,*, GUANFU WANG1, JIAXI CHEN1,2,#,*

    Oncology Research, Vol.32, No.4, pp. 717-726, 2024, DOI:10.32604/or.2023.043575

    Abstract The long non-coding RNA, Negative Regulator of Antiviral Response (NRAV) has been identified as a participant in both respiratory virus replication and immune checkpoints, however, its involvement in pan-cancer immune regulation and prognosis, particularly those of hepatocellular carcinoma (HCC), remains unclear. To address this knowledge gap, we analyzed expression profiles obtained from The Cancer Genome Atlas (TCGA) database, comparing normal and malignant tumor tissues. We found that NRAV expression is significantly upregulated in tumor tissues compared to adjacent nontumor tissues. Kaplan-Meier (K-M) analysis revealed the prognostic power of NRAV, wherein overexpression was significantly linked to… More >

  • Open Access

    ARTICLE

    Developing risk models and subtypes of autophagy-associated LncRNAs for enhanced prognostic prediction and precision in therapeutic approaches for liver cancer patients

    LU ZHANG*, JINGUO CHU*, YUSHAN YU

    Oncology Research, Vol.32, No.4, pp. 703-716, 2024, DOI:10.32604/or.2023.030988

    Abstract Background: Limited research has been conducted on the influence of autophagy-associated long non-coding RNAs (ARLncRNAs) on the prognosis of hepatocellular carcinoma (HCC). Methods: We analyzed 371 HCC samples from TCGA, identifying expression networks of ARLncRNAs using autophagy-related genes. Screening for prognostically relevant ARLncRNAs involved univariate Cox regression, Lasso regression, and multivariate Cox regression. A Nomogram was further employed to assess the reliability of Riskscore, calculated from the signatures of screened ARLncRNAs, in predicting outcomes. Additionally, we compared drug sensitivities in patient groups with differing risk levels and investigated potential biological pathways through enrichment analysis, using… More >

  • Open Access

    ARTICLE

    Bioinformatics analysis and experimental validation of cystathionine-gamma-lyase as a potential prognosis biomarker in hepatocellular carcinoma

    YANAN MA1, SHANSHAN WANG2,*, HUIGUO DING1,*

    BIOCELL, Vol.48, No.3, pp. 463-471, 2024, DOI:10.32604/biocell.2024.048244

    Abstract Background: Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis and high mortality worldwide. Although cystathionine-gamma-lyase (CSE) plays an important role in the development of multiple tumors, the clinical implication and potential mechanisms of CSE in HCC development remain elusive. Methods: In our study, the CSE expression in HCC was analyzed in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets and further confirmed by RT-qPCR and immunohistochemistry assays in HCC samples. Furthermore, the associations between CSE expression and HCC malignancy as well as survival were analyzed in GSE14520 and validated… More >

  • Open Access

    REVIEW

    A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma

    ELHAM AMJAD1, RAFFAELE PEZZANI2,3,*, BABAK SOKOUTI1,*

    Oncology Research, Vol.32, No.3, pp. 439-461, 2024, DOI:10.32604/or.2023.044473

    Abstract Noncoding RNAs instruct the Cas9 nuclease to site-specifically cleave DNA in the CRISPR/Cas9 system. Despite the high incidence of hepatocellular carcinoma (HCC), the patient’s outcome is poor. As a result of the emergence of therapeutic resistance in HCC patients, clinicians have faced difficulties in treating such tumor. In addition, CRISPR/Cas9 screens were used to identify genes that improve the clinical response of HCC patients. It is the objective of this article to summarize the current understanding of the use of the CRISPR/Cas9 system for the treatment of cancer, with a particular emphasis on HCC as… More >

  • Open Access

    ARTICLE

    Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2α

    KUO-SHYANG JENG1, PO-YU CHENG2, YUEH-HSIEN LIN2, PO-CHUN LIU2, PING-HUI TSENG3, YU-CHAO WANG4, CHIUNG-FANG CHANG5, CHUEN-MIIN LEU2,*

    Oncology Research, Vol.32, No.1, pp. 163-174, 2024, DOI:10.32604/or.2023.030975

    Abstract Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. Current therapies are effective for HCC patients with early disease, but many patients suffer recurrence after surgery and have a poor response to chemotherapy. Therefore, new therapeutic targets are needed. We analyzed gene expression profiles between HCC tissues and normal adjacent tissues from public databases and found that the expression of genes involved in lipid metabolism was significantly different. The analysis showed that AKR1C3 was upregulated in tumors, and high AKR1C3 expression was associated with a poorer prognosis in HCC patients. In vitro, assays demonstrated that… More >

  • Open Access

    ARTICLE

    Silencing of peroxiredoxin 2 suppresses proliferation and Wnt/β-catenin pathway, and induces senescence in hepatocellular carcinoma

    XUEGANG YANG1,#, XIANHONG XIANG2,3,#, GUOHUI XU1, SHI ZHOU3, TIANZHI AN3,4,*, ZHI HUANG3,4,*

    Oncology Research, Vol.32, No.1, pp. 213-226, 2024, DOI:10.32604/or.2023.030768

    Abstract Hepatocellular carcinoma (HCC), a common malignancy worldwide, still lacks effective clinical treatment. The study aimed to investigate the oncogenes that affect the progression of HCC and their possible mechanisms. In our study, we initially confirmed a higher level of PRDX2 in the bile of HCC patients compared to those with choledocholithiasis by 2-DE, LC-MS, and ELISA. Subsequently, we demonstrated the high expression of peroxiredoxin 2 (PRDX2) in HCC based on the TCGA database and clinical sample analysis. Furthermore, PRDX2 overexpression enhanced the viability of HCC cells. And PRDX2 silencing induced senescence of HCC cells. In vivo, More >

Displaying 1-10 on page 1 of 66. Per Page